| FDA Gives Favorable Review to SHARP Ahead of Vytorin Advisory Panel - Forbes |
|
|
Forbes In preparation for Wednesday's meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee, an FDA reviewer has generally endorsed the positive interpretation of the SHARP (Study of Heart and Renal Protection) trial of Vytorin (ezetimibe |